HF's ability to overcome DDP resistance in NSCLC through dual suppression of the PI3K/AKT and MAPK pathways highlights its potential as a synergistic therapeutic agent for enhancing treatment efficacy. Here, PIK3CB is linked to non-small cell lung carcinoma.